bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 2162: KIM–1 mediatesimmune evasioninrenal cell carcinoma
Authors: Yotis Demitra M. , Shrum Bradly , Sarabusky Marie , Gunaratnam Lakshman 
Published: September 2020

Abstract
Renal cell carcinoma (RCC) is the most common and lethal form of kidney cancer. Cancer immune evasion is a major obstacle for effective immunotherapy in RCC. Mechanisms of immune evasion are characterized by three phenotypes: Immune Inflamed; tumor contains infiltrating T cells which are rendered inactive within the tumor microenvironment due to localized inhibition. Immune Desert; tumor is devoid of activate T cells due to defective antigen presentation, and/or T cell activation. Lastly, Immune Excluded; tumor is surrounded by T cells that are unable to penetrate the parenchyma, caused by immunosuppression within the tumor stroma. Kidney Injury Molecule-1 (KIM-1) is a cell-surface glycoprotein aberrantly expressed in &gt;90% of RCC tumors. The purpose of this study was to determine the pathophysiological significance of KIM-1 in RCC pathogenesis. We generated murine RCC cells (Renca) expressing KIM-1 (KIM-1pos) or control vector (KIM-1neg) using lentiviral transduction. We found that KIM-1 expression on RCC cells promoted more rapid tumor growth when injected contralaterally into syngeneic immunocompetent BALB/c mice (KIM-1neg = 263.75mm3, KIM-1pos = 849.72, p = 0.0149 & KIM-1neg = 0.32g, KIM-1pos = 0.58, p = 0.0229), but not in RAG1-/- immunodeficient BALB/c mice suggesting the KIM-1 promotes tumor growth through evasion of the adapt immune system. When analyzing tumor infiltrating lymphocytes (TILs) from both tumor groups, we found a relative scarcity of CD4+ and CD8+ T cells within the KIM-1pos vs. KIM-1neg tumors. To classify the immune evasion phenotype, we analyzed localization of the immune infiltrate using immunofluorescence within KIM-1pos and KIM-1neg RCC tumors. We found significantly fewer CD3+ cells within the KIM-1pos vs. KIM-1neg tumor parenchyma (KIM-1neg = 3625.78%, KIM-1pos = 272.36%, p = 0.0410). Moreover, CD3+ cells of the KIM-1neg tumors were observed in the parenchyma, whereas CD3+ cells of the KIM-1pos tumors were localized to the tumor stroma. In addition, we observed a higher frequency of myeloid derived suppressor cells (MDSCs) within the KIM-1pos vs the KIM-1neg tumor parenchyma (KIM-1neg = 0.05, KIM-1pos = 0.19, p = 0.0266). Transcriptomic profiling of both KIM-1pos and KIM-1neg Renca cells suggests that KIM-1 promotes deposition of extracellular matrix (KIM-1neg = -1.21, KIM-1pos = 1.96-fold change), which may contribute to KIM-1-mediated immune evasion Our data suggests that KIM-1 expression in RCC promotes immune evasion by altering the tumor microenvironment resulting in an Immune Excluded phenotype.
Citation Format: Demitra M. Yotis, Bradly Shrum, Marie Sarabusky, Lakshman Gunaratnam. KIM–1 mediatesimmune evasioninrenal cell carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2162.
Abstract 2206: Degradation of hyaluronan in the tumor microenvironment enhances oncolytic reovirus and anti-PD-L1 therapy in a murine syngeneic breast tumor model
Authors: Lee Jisook , Wilkinson Grey A. , Kimbler Trevor , Blouw Barbara , Thompson Curtis B. 
Published: September 2020

Abstract
The extracellular matrix (ECM) structure heavily influences tumor growth, invasion and various steps of the cancer-immunity cycle. Hyaluronan (HA), a major component of ECM, is a glycosaminoglycan that accumulates in the tumor microenvironment (TME) of many solid tumor types, and HA accumulation can restrict T cell infiltration and promote immunosuppression. We have demonstrated in preclinical tumor models that enzymatic degradation of TME HA by intravenous PEGylated recombinant human hyaluronidase PH20 (Pegvorhyaluronidase alfa, PEGPH20) facilitates delivery of chemotherapeutics to tumors and enhances efficacy of current immunotherapy strategies including checkpoint inhibitors. In this study, we hypothesized that degradation of HA with PEGPH20 treatment may remodel the TME to improve the efficacy of oncolytic reovirus therapy (pelareorep) and checkpoint blockade therapy. To test this hypothesis, EMT6 murine breast tumor cells, which spontaneously accumulate HA and are sensitive to oncolytic activity of pelareorep were implanted orthotopically into the mammary fat pad of BALB/c mice. In this model, PEGPH20 treatment resulted in a reduction of HA measured by immunohistochemistry and induced tumor growth inhibition (30% TGI). Pelareorep plus anti-PD-L1 treatment also resulted in anti-tumor activity (44% TGI), and flow cytometric analysis of tumor infiltrating immune cells in pelareorep + anti-PD-L1-treated tumors demonstrated a significant increase in the numbers of cytotoxic CD8+ tumor infiltrating lymphocytes (TILs, p=0.0004), a decrease in regulatory T cells (T reg, p&lt;0.0001) and an increase in CD8:Treg ratio (p=0.0018), indicating a robust antitumor immune response. Combination of PEGPH20 with pelareorep + anti-PD-L1 resulted in enhanced anti-tumor activity (71% TGI) compared to either PEGPH20 (30%TGI) or pelareorep + anti-PD-L1 (44% TGI). PEGPH20 in combination with pelareorep + anti-PDL1 also extended survival (median survival time, MST- 30 days, p&lt;0.0001) in comparison with PEGPH20 alone (MST-21 days) or pelareorep + anti-PD-L1 (MST-22 days). Our data demonstrate the potential for matrix modeling through degradation of HA as a strategy to improve oncolytic reovirus + anti-PD-L1 immunotherapy. These findings are consistent with prior preclinical studies and support clinical evaluation of combining PEGPH20 with immune checkpoint inhibitors in HA-accumulating tumors.
Citation Format: Jisook Lee, Grey A. Wilkinson, Trevor Kimbler, Barbara Blouw, Curtis B. Thompson. Degradation of hyaluronan in the tumor microenvironment enhances oncolytic reovirus and anti-PD-L1 therapy in a murine syngeneic breast tumor model [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2206.
Abstract 2253: Lymphangiogenesis augments the anti-tumor efficacy of radiotherapy in mouse melanoma
Authors: Mitrousis Nikolaos , Sasso Maria Stella , Weichselbaum Ralph R. , Hubbell Jeffrey A. , Swartz Melody A. 
Published: September 2020

Abstract
Radiotherapy (RT) constitutes a significant component of cancer therapy in the clinic, with approximately 50% of all cancer patients receiving treatment over the course of their disease. In addition to acting as a DNA-damaging agent, RT leads to the release of tumor antigens, damage-associated molecular patterns, and cytokines, a process termed immunogenic cell death. This phenomenon triggers the initiation of anti-tumor immune responses, which have been shown to be essential for the complete therapeutic response to RT. Despite its diverse mechanisms of action and broad applicability, RT does not typically lead to curative responses and combinations with other treatment modalities such as immunotherapy are being explored to improve efficacy. Our laboratory and others have previously established that tumor-associated lymphatics can actively modulate anti-tumor immune responses and potentiate immunotherapy. Here, we asked whether lymphangiogenesis influences the immune response and anti-tumor efficacy elicited by RT. We employed two variants of the aggressive B16F10 melanoma model: a variant that was transduced to overexpress the lymphangiogenic factor VEGF-C (B16-VEGF-C), and a mock-transduced (B16-ctrl) variant. Tumor-bearing animals were treated by ablative doses of localized RT and monitored for tumor growth and survival, while anti-tumor immune responses were assessed by flow cytometry and ELISA. We observed that the therapeutic efficacy of RT was greater in B16-VEGF-C melanomas compared to B16-ctrl, as evidenced by a significant inhibition of tumor growth and extended animal survival. In line with this finding, B16-VEGF-C melanomas exhibited a significantly higher CD8+ T cell infiltration and activation upon ex vivo restimulation after RT. These responses were partially inhibited by a function-blocking antibody of the main VEGF-C receptor, VEGFR3. To gain further insight, we assessed the tumor infiltration and activation status of antigen-presenting cells. Consistent with the observed T cell response, we found that both dendritic cells and macrophages exhibited a greater expression of co-stimulatory molecules in B16-VEGF-C melanomas after RT. Together, our findings demonstrate that lymhangiogenesis may be a key contributing factor underlying tumor responsiveness to RT.
Citation Format: Nikolaos Mitrousis, Maria Stella Sasso, Ralph R. Weichselbaum, Jeffrey A. Hubbell, Melody A. Swartz. Lymphangiogenesis augments the anti-tumor efficacy of radiotherapy in mouse melanoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2253.
Abstract 2276: Preclinical development and mechanism of action studies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate
Authors: Snell Daniel , Gunde Tea , Warmuth Stefan , Lichtlen Peter , Tietz Julia , Brock Matthias , Simonin Alexandre , Hess Christian , Christopher Weinert , Heiz Robin , Flueckiger Naomi , Zeberer Julia , Diem Dania , Mahler Dana , Morenzoni Diego , Wickihalder Belinda , Muntwiler Simone , Poelderl Antonia , Kuettner Benjamin , Wagen Sandro , Meyer Sebastian , Egan Timothy , Urech David 
Published: September 2020

Abstract
Antagonistic molecules targeting the PD-1/PD-L1 axis have shown excellent activity in the clinic. However the majority of patients do not respond to the therapy due to multifaceted reasons implicating a non-effective activation of the immune system in those patients. The co-stimulatory molecule 4-1BB has been shown to be a key signalling component of T cells and the combination of 4-1BB activation and PD-1/PD-L1 antagonism has been shown to be highly active in preclinical models. Systemic application of first generation anti-4-1BB antibodies however have resulted in dose limiting hepatic toxicities. We have generated a novel 4-1BB/PD-L1/HSA trispecific MATCH3 immunomodulatory drug candidate (NM21-1480) that agonizes 4-1BB conditionally upon PD-L1 binding / blockade. Here we show the preclinical development data package for NM21-1480 demonstrating exquisite tumour-specific T cell activation associated with both 4-1BB agonism as well as PD-L1/PD-1 antagonism. We also demonstrate tumour specific localisation and accumulation of NM21-1480 in a mouse xenograft model. We report on the toxicity profile and pharmacokinetic properties of the molecule in non-human primates. We plan to initiate a first-in-human clinical study in the second half of 2020 to determine the safety, tolerability and first signs of clinical activity of the molecule.
Citation Format: Daniel Snell, Tea Gunde, Stefan Warmuth, Peter Lichtlen, Julia Tietz, Matthias Brock, Alexandre Simonin, Christian Hess, Weinert Christopher, Robin Heiz, Naomi Flueckiger, Julia Zeberer, Dania Diem, Dana Mahler, Diego Morenzoni, Belinda Wickihalder, Simone Muntwiler, Antonia Poelderl, Benjamin Kuettner, Sandro Wagen, Sebastian Meyer, Timothy Egan, David Urech. Preclinical development and mechanism of action studies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2276.
Abstract 2322: A polygenic risk score-based genetic stratification for endometrial cancer
Authors: Bafligil Cemsel , Thompson Deborah J. , Lophatananon Artitaya , Smith Miriam J. , Dennis Joe , Evans Gareth D. , Crosbie Emma J. 
Published: September 2020

Abstract
Endometrial cancer (EC) is the most common of gynecological cancers in the UK. There is evidence for genetic predisposition to EC, however, single nucleotide polymorphisms have not been considered in risk prediction models so far. We hypothesized that a polygenic risk score (PRS) based on a panel of robust SNPs may be useful to predict women at high risk of developing EC. We conducted a systematic review to identify the most robust SNPs which may be associated with EC risk. The resulting panel of SNPs was validated in an independent cohort comprising EC cases, and control women with intact uterus. In the present study, we used 560 cases and 1202 controls of broad-European origin to construct a PRS. Our systematic review suggested twenty four SNPs, nineteen of which were reported to reach genome-wide significance in large GWAS. Preliminary results using 560 cases and 1202 controls produced effect sizes, directions and dosages similar to published data. The mean PRS for EC cases was 0.64 (SD=0.43, 95%CI 0.60-0.68) while mean PRS for controls was 0.48 (SD=0.42, 95% CI 0.46-0.51). The AUC of the PRS achieved was 0.61. Women in the highest tertile of the PRS score had a 2.4 times increased risk of developing EC compared to women in the lowest tertile (OR=2.40, 95%CI 1.85-3.09, p = 1.47E-11). Women in the mid tertile also had a modestly increased risk of EC compared to the lowest tertile (OR=1.40, 95%CI 1.06-1.84, p = 0.017). There was a clear trend of increasing risk with category (p = 6.25E-12). There is mounting evidence for polygenic input from common variants in EC susceptibility. Our results, for the first time, validate the potential use of a PRS for risk stratification of women at high risk of EC. When considered alongside epidemiological risk factors, the PRS could provide a good discrimination for early detection and prevention of EC in a clinical setting.
Citation Format: Cemsel Bafligil, Deborah J. Thompson, Artitaya Lophatananon, Miriam J. Smith, Joe Dennis, Gareth D. Evans, Emma J. Crosbie. A polygenic risk score-based genetic stratification for endometrial cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2322.
Abstract 233: Tumor-associated carbonic anhydrase IX maintains cellular proliferation by regulating tumor metabolism: a novel link revealed by proteomics
Authors: Benej Martin , Svastova Eliska , Banova Radivojka , Kopacek Juraj , Gibadulinova Adriana , Kery Martin , Arena Simona , Scaloni Andrea , Vitale Monica , Zambrano Nicola , Papandreou Ioanna , Denko Nicholas C. , Pastorekova Silvia 
Published: September 2020

Abstract
Tumor hypoxia is a critical microenvironmental stress occurring in virtually all types of solid tumors. Survival of cancer cells is dependent upon their ability to adapt to these limiting conditions. Hypoxia-induced carbonic anhydrase IX (CA IX) plays a crucial adaptive role in response to hypoxic and acidic microenvironments by catalytically hydrating extracellular CO2 to produce bicarbonate ions that maintain intracellular pH (pHi). In order to determine how CAIX function impacts other cellular processes, we used proteomic profiling to identify changes in response to transient CA IX knockdown in hypoxia. We discovered a significant reduction of key glycolytic enzyme levels with a most prominent decrease in lactate dehydrogenase (LDH). Our data shows that in addition to participating in cellular regulation of pHi, CA IX significantly stimulates glycolytic flux, lactate production and rate of proliferation in hypoxia. Because LDH activity contributes to pHi regulation by consuming cytoplasmic protons in the process of NADH regeneration, CA IX knockdown-mediated LDH suppression may further compromise the pHi regulating ability in hypoxia. Interestingly, addition of the alternative LDH substrate alpha-ketobutyrate compensates for reduced lactate production and restores pHi and proliferation in CA IX-deficient cells. These findings suggest that CA IX confers adaptive plasticity and supports proliferation of cancer cells both directly and indirectly - through its effect as a pHi regulator and by maintaining glycolysis-permissive intracellular environment, respectively. Because CA IX expression is limited almost exclusively to tumors, our findings highlight the role as well as provide mechanistic insight for the utility of CA IX as an anti-cancer target and suggests that highly glycolytic tumors might be particularly vulnerable to CA IX-targeted therapy.
Citation Format: Martin Benej, Eliska Svastova, Radivojka Banova, Juraj Kopacek, Adriana Gibadulinova, Martin Kery, Simona Arena, Andrea Scaloni, Monica Vitale, Nicola Zambrano, Ioanna Papandreou, Nicholas C. Denko, Silvia Pastorekova. Tumor-associated carbonic anhydrase IX maintains cellular proliferation by regulating tumor metabolism: a novel link revealed by proteomics [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 233.
Abstract 2332: Correlation of lifestyle factors with epigenetic aging unveiled in the practice of a DNA methylation-based age test
Authors: Guo Wei , Chew Yap Ching , Yang Xiaojing , Suwoto Michiko , Yamada Taikun , Jia Xi Yu 
Published: September 2020

Abstract
Background: DNA methylation clocks have been developed recently to estimate epigenetic age which is associated with chronological age in mouse and human. Changes in epigenetic age were reported in patients with health conditions including cancer. Different from genetic variations, epigenetic properties can be modified by environmental factors. Epigenetic age tests using blood samples have been offered directly to customers recently. We sought to analyze relationships between epigenetic aging and lifestyle factors, medication and aging interventions in the hope of assisting healthier living.
Methods: Epigenetic age, called DNAge, is estimated using linear regression of DNA methylation levels at 206 loci containing 1344 CpGs and chronological age. Delta age is defined as the difference of epigenetic age minus chronological age. Correlations between lifestyle factors or medication and delta age of hundreds of whole blood samples were evaluated using biweight midcorrelation. Statistical significance is set at 0.05.
Results: Our results showed positive correlations between accelerated epigenetic aging and BMI (bicor=0.148, p=0.009, n=311), current smoker (bicor=0.143, p=0.011, n=315), or stress (bicor=0.088, p=0.128, n=302). Factors with positive correlation but not reaching statistical significance included total cholesterol, alcohol consumption and Keto diet. Factors with negative correlation but not statistically significant included exercise, balanced diet, mostly meat, mostly vegetables, and education.
Conclusions: The epigenetic age analysis of real customer data confirmed beneficial and adversarial health effects of certain lifestyle factors. The DNAge test offered proves to be useful as a biomarker for biological age and as a practical tool for monitoring and evaluation of health status which may be used in cancer epidemiology study and help cancer prevention.
Citation Format: Wei Guo, Yap Ching Chew, Xiaojing Yang, Michiko Suwoto, Taikun Yamada, Xi Yu Jia. Correlation of lifestyle factors with epigenetic aging unveiled in the practice of a DNA methylation-based age test [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2332.
Abstract 2335: Heterozygous PALB2 mutations cause replication stress and DNA repair defects in carrier derived lymphoblastoid cell lines
Authors: Laurila Niina , Borgmann Kerstin , Bose Muthiah , Meyer Felix , Pylkäs Katri , Xia Bing , Foulkes William , Southey Melissa , Pospiech Helmut , Winqvist Robert 
Published: September 2020

Abstract
During the last decade, PALB2 has been defined as a high-risk breast cancer susceptibility gene alongside BRCA1 and BRCA2. Heterozygous mutation in PALB2 increases the lifetime breast cancer risk of female carriers to an average of 53%, but the risk estimate is affected by family history, studied population, and the specific pathogenic variant.
We have previously shown that lymphoblastoid cell lines (LCLs) of persons heterozygous for PALB2 c.1592delT, a Finnish founder mutation, show defects in DNA replication and damage response. Now we examine how various heterozygous, protein-truncating PALB2 founder mutations from different populations affect cell function, and whether the observed phenotype correlates with disease risk. The study cohorts come from Canada, Australia, and Finland and consist of 80 LCLs of PALB2 mutation carriers (c.1592delT, c.2323C&gt;T, c.3113G&gt;A or c.3323delA) and suitable population controls. There is some evidence that these variants are associated with different magnitudes of breast cancer risk, and PALB2 c.3113G&gt;A has been associated with an exceptionally high cancer risk of 91% (95% CI 44-100) to age 70.
Utilizing these LCLs, we have studied DNA damage response, cell cycle progression, and DNA replication with various methods. DNA fiber assay results show that PALB2 mutation carriers elongate their DNA more slowly during replication, likely due to increased fork stalling, but compensate this by increased dormant origin firing. The strongest replication phenotype was observed for PALB2 c.3113G&gt;A carriers. High content analysis shows that most of the mutation carriers had compromised RAD51 foci formation after DNA damage, whereas 53BP1 foci levels were elevated. These results indicate that during DNA double-strand break repair, heterozygous PALB2 mutation carriers may rely more on alternative, error-prone pathways that are independent of RAD51, thus contributing to genomic instability. Additionally, we are currently performing RNA-Seq to determine if the LCLs show adaptation of their gene expression in response to pathogenic PALB2 variants.
Citation Format: Niina Laurila, Kerstin Borgmann, Muthiah Bose, Felix Meyer, Katri Pylkäs, Bing Xia, William Foulkes, Melissa Southey, Helmut Pospiech, Robert Winqvist. Heterozygous PALB2 mutations cause replication stress and DNA repair defects in carrier derived lymphoblastoid cell lines [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2335.